WorkThe story, in brief
The past, present and future of de novo protein design - Nature
After mapping 200M proteins, AI enters the drug discovery race—designing molecules on demand instead of screening them.
The KeyNews take
Why it matters
AI-driven de novo protein design is moving from research benchmark to practical drug/enzyme development, with implications for pharma R&D timelines, vaccine development, and industrial biotech. Leaders need to understand how this reshapes competitive advantage in life sciences.
The key facts
5 to know200M+ proteins mapped by AI systems
De novo protein design now targeting drug acceleration, vaccine development, and industrial enzymes
Applications include plastic degradation and CO₂ reduction enzymes
Shift from protein discovery to on-demand molecular design
Adaptyv contest tracking AI progress in harder design targets
Go to the source
Reuters Technologynews.google.com
Publisher excerpt: The past, present and future of de novo protein design Nature AI keeps tackling harder targets in protein design, latest Adaptyv contest shows Endpoints News How AI and Automation Are Reshaping Protein Design Technology Networks After mapping more than 200 million proteins, artificial intelligence…